Dr. David H Birnie, MD
Claim this profileUniversity of Ottawa Heart Institute
Studies Atrial Fibrillation
Studies Sarcoidosis
5 reported clinical trials
10 drugs studied
Affiliated Hospitals
Clinical Trials David H Birnie, MD is currently running
Prednisone/Prednisolone Dosing
for Cardiac Sarcoidosis
Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated. The Investigators hypothesize that low dose Prednisone(or Prednisolone)/Methotrexate combination will be as effective as standard dose Prednisone(or Prednisolone), and result in significantly better quality of life and less toxicity than standard dose Prednisone(or Prednisolone).
Recruiting4 awards Phase 35 criteria
Corticosteroids
for Cardiac Sarcoidosis
Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS) of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon. A Canadian physician survey found that most physicians do not investigate for CS as a possibility in these situations. Thus many patients with clinically important CS are going un-diagnosed. A study from Finland showed that missing the diagnosis of CS in these patients' leads to significant mortality and morbidity. There are no published clinical consensus guidelines on treatment of CS. Corticosteroid therapy is advocated by most experts. This is based on very modest data from small retrospective observational studies using variable definitions of clinical response. The effect of corticosteroid treatment on the clinical course of CS has not been studied in prospective studies and will be one of the aims of this project. Recent physician surveys regarding CS, in Canada and the US, found that current clinical practice varies widely. The 2008 American College of Cardiology/American Heart Association/Heart Rhythm society guidelines recommend implantation of a defibrillator (Class IIa recommendation) to prevent sudden cardiac death. The most recent Canadian device therapy guidelines do not mention CS. A multi-center collaborative approach to study CS is greatly needed." The investigators propose exactly that i.e. a multi-center prospective cohort to start to answer clinical questions. The investigators have formed the CANADIAN CARDIAC SARCOIDOSIS RESEARCH GROUP. The group includes respirologists with an interest in sarcoidosis, cardiac electrophysiologists, cardiac imaging specialists with extensive experience in imaging of sarcoidosis and biostatisticians. The research will be in two phases; a registry of current diagnostic approaches, treatment and prognosis, and a randomized clinical trial of the effect of corticosteroid treatment on the clinical course of cardiac sarcoidosis.
Recruiting1 award N/A10 criteria
More about David H Birnie, MD
Clinical Trial Related14 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments David H Birnie, MD has experience with
- Optimal Medical Therapy Plus CRT/ICD
- Optimal Medical Therapy Plus ICD
- Methotrexate
- Prednisone
- Prednisone Or Prednisolone
- Corticosteroid Therapy
Breakdown of trials David H Birnie, MD has run
Atrial Fibrillation
Sarcoidosis
Cardiac Sarcoidosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David H Birnie, MD specialize in?
David H Birnie, MD focuses on Atrial Fibrillation and Sarcoidosis. In particular, much of their work with Atrial Fibrillation has involved treating patients, or patients who are undergoing treatment.
Is David H Birnie, MD currently recruiting for clinical trials?
Yes, David H Birnie, MD is currently recruiting for 2 clinical trials in Ottawa Ontario. If you're interested in participating, you should apply.
Are there any treatments that David H Birnie, MD has studied deeply?
Yes, David H Birnie, MD has studied treatments such as Optimal Medical therapy plus CRT/ICD, Optimal Medical therapy plus ICD, Methotrexate.
What is the best way to schedule an appointment with David H Birnie, MD?
Apply for one of the trials that David H Birnie, MD is conducting.
What is the office address of David H Birnie, MD?
The office of David H Birnie, MD is located at: University of Ottawa Heart Institute, Ottawa, Ontario K1W 4W7 Canada. This is the address for their practice at the University of Ottawa Heart Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.